Corvus Pharma Q1 2025: Assets $68.17M, Liabilities $67.90M
Ticker: CRVS · Form: 10-Q · Filed: May 8, 2025 · CIK: 1626971
| Field | Detail |
|---|---|
| Company | Corvus Pharmaceuticals, Inc. (CRVS) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, licensing
TL;DR
Corvus Pharma's Q1 2025: Assets $68.17M, Liabilities $67.90M. Licensing deals ongoing.
AI Summary
Corvus Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $68,169,461 and total liabilities of $67,899,779 as of March 31, 2025. The filing also details various license agreements, including those with Vernalis R&D Limited, Scripps Research Institute, and Monash License, with terms extending through the reporting period.
Why It Matters
This filing provides a snapshot of Corvus Pharmaceuticals' financial health and ongoing licensing activities, crucial for understanding its operational status and future development potential.
Risk Assessment
Risk Level: medium — The company has a very narrow margin between assets and liabilities, indicating potential financial strain.
Key Numbers
- $68.17B — Total Assets (As of March 31, 2025)
- $67.90B — Total Liabilities (As of March 31, 2025)
Key Players & Entities
- Corvus Pharmaceuticals, Inc. (company) — Filer
- March 31, 2025 (date) — Reporting period end date
- $68,169,461 (dollar_amount) — Total assets as of March 31, 2025
- $67,899,779 (dollar_amount) — Total liabilities as of March 31, 2025
- Vernalis R&D Limited (company) — Licensing partner
- Scripps Research Institute (company) — Licensing partner
- Monash License (company) — Licensing partner
FAQ
What was Corvus Pharmaceuticals' net income or loss for the quarter ending March 31, 2025?
The provided excerpt does not contain specific net income or loss figures for the quarter ending March 31, 2025.
What are the specific terms of the license agreement with Vernalis R&D Limited mentioned in the filing?
The filing indicates license agreement terms with Vernalis R&D Limited were active from January 1, 2025, to March 31, 2025, and also from February 1, 2017, but does not detail the specific terms.
What is the fair value of the warrants held by Corvus Pharmaceuticals as of March 31, 2025?
The filing indicates that warrants are a member of fair value measurements recurring, with Level 3 inputs, as of March 31, 2025, but does not provide the specific fair value amount.
How has the company's financial position changed from December 31, 2024, to March 31, 2025?
The filing shows that as of December 31, 2024, warrants were also a component of recurring fair value measurements with Level 3 inputs, but specific comparative financial position changes are not detailed in this excerpt.
Are there any significant changes in the company's debt structure reported in this 10-Q?
This excerpt does not provide information regarding changes in the company's debt structure.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Corvus Pharmaceuticals, Inc. (CRVS).